Steven Cohen Dia Medica Therapeutics Inc. Put Options Transaction History
Point72 Asset Management, L.P.
- $39.3 Billion
- Q1 2024
Put Options
0 transactions
| Quarter | Operation | Price Per put | puts change | puts Held | SEC Form |
|---|
Others Institutions Holding DMAC
# of Institutions
33Shares Held
3.85MCall Options Held
5.9KPut Options Held
1.4K-
Vanguard Group Inc Valley Forge, PA1.01MShares$2.94 Million0.0% of portfolio
-
First Manhattan CO New York, NY850KShares$2.47 Million0.01% of portfolio
-
Paragon Associates & Paragon Associates Ii Joint Venture Dallas, TX500KShares$1.45 Million2.47% of portfolio
-
Geode Capital Management, LLC Boston, MA239KShares$693,7810.0% of portfolio
-
Bleichroeder LP New York, NY222KShares$644,7190.19% of portfolio
About DiaMedica Therapeutics Inc.
- Ticker DMAC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 26,443,100
- Market Cap $76.7M
- Description
- DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type...